coronavirus treatment

U.S. regulators have ended one of Eli Lilly’s COVID-19 antibody trials early after data suggested the drug was “unlikely to help” coronavirus patients recover.

The World Health Organization released the findings of their coronavirus therapeutics study on Friday, which studied the impact of drugs like remdesivir and hydroxychloroquine on treating hospitalized coronavirus patients.

Eli Lilly’s late-stage trial of its monoclonal antibody coronavirus treatment was paused by U.S. regulators over potential safety concerns.

President Donald Trump briefly left Walter Reed Medical Center in his motorcade to salute at supporters outside the hospital. Trump was admitted to Walter Reed for COVID treatment on Friday. Doctors have said the president is doing “well” and could return to the White House as early as Monday.

Doctors treating President Donald Trump for the coronavirus at Walter Reed Medical Center gave updates on the president’s treatment on Saturday morning. “At this time, the team and I are extremely happy with the progress the president has made,” said the president’s physician, Dr. Sean Conley.

With 74-year-old President Trump and 50-year-old first lady Melania Trump testing positive for the coronavirus, what are the best proven treatments for them and other patients?

The nearly 1 million people who have lost their lives to COVID-19 also have given the world a gift: a better understanding of how to treat the disease.

The effects of the coronavirus can vary dramatically from person to person. Some may have mild symptoms, while others suffer extreme symptoms and even death. AI therapeutics in Guilford is working on a drug that they say can slow those symptoms at the start. “This is an oral pill that you take, we have five million that we’re making,...

One Connecticut company is working on a drug to slow the progression of COVID-19 in people who are already infected.

Pharmaceutical giant Gilead says it plans to charge at least $2,300 for a single treatment course of Remdesivir, a drug shown to shorten recovery time for severely ill coronavirus patients.

A new study out of the University of Minnesota suggests that anti-malarial drug hydroxychloroquine has no effect on preventing patients from contracting the novel coronavirus.

It has been six months since the start of the novel coronavirus outbreak, and what we have learned about the deadly disease that upended our lives has changed considerably. Dr. Summer McGee, dean of the School of Public Health at the University of New Haven, gave her take on the evolution of our understanding of the deadly coronavirus, six months…

We look back at what we’ve learned over the last six months and what the future against the virus looks like

Results from a phase three trial show that Remdesivir helps recovery in moderately-ill coronavirus patients.

At a press conference on Monday, Admiral Brett Giroir, assistant secretary for health, confirmed that HHS is working with a network of children’s hospitals and intensive care units to better understand the extreme coronavirus symptoms in infected children.

Companies around the world are working on vaccines and treatments for the coronavirus, and that includes the Pfizer lab in Groton. They’ve already started human clinical trials of a vaccine they believe could be available as soon as September. Inside the Pfizer lab in Groton there’s a two-prong approach to defeating COVID-19: developing treatments and developing a vaccine. The...

WHO Director-General Dr. Tedros Adhanom Ghebreyesus on Monday announced 40 countries have united to pledge billions of dollars to help find a vaccine to fight the coronavirus pandemic.

When asked if he takes responsibility for the spike in calls to poison control centers around the country following his on-camera comments about bleach and disinfectant injection as a potential coronavirus treatment, President Donald Trump said, “I can’t imagine why.”

Patients with COVID-19 could see results from blood plasma treatment within days.

Trinity Health of New England is working on a clinical trial using blood plasma with antibodies from recovered COVID-19 patients to treat critically ill patients.